690 results about "Drug delivery" patented technology

The present disclosure relates to a medicament delivery device comprising a housing having a proximal end and contains a container of medicament positioned within the housing in a medicament container holder. The medicament container can be dual chambered, for example a pre-filled medicament container having a needle, a dose of medicament and one or more sliding stoppers. The medicament container holder can be configured with a recess or pocket to accommodate the loading of a dual chambered container and interact with an inside surface of the housing to rotationally fix the container holder relative to the housing and the medicament container. A tubular activation member, e.g., a needle cover, is slidably positioned within a housing of the delivery device to move from a first position to a second position, and then to a final locked position. A plunger rod can only move proximally relative to the needle cover when the needle cover is in the second position.

Provided herein are drug delivery systems and methods for locally delivering therapeutic agents, as well as methods for using such drug delivery systems for the treatment of disease.

The present invention relates to a near-infrared responsive drug delivery system, wherein a near-infrared responsive drug delivery system comprising a near-infrared responsive drug delivery formulation is provided, and the near-infrared responsive drug delivery formulation may include a near-infrared responsive material that generates heat in response to near-infrared rays, and a drug loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material.

This invention relates to the field of infusion rate control technology, specifically to an adaptive adjustment method for intraoperative anesthetic drug infusion rate based on reinforcement learning. The method includes the following steps: monitoring tubing pressure waveforms to extract hysteresis response features; constructing a multidimensional fluid environment state vector by splicing anesthesia depth errors; inputting the vector into a neural network to map and output a composite command containing a base flow rate and resistance torque; establishing a corrected drive signal by superimposing acceleration pulses based on tubing stiffness and compensating for flow leakage; and completing closed-loop verification based on pressure change rate deviation. In this invention, by analyzing the establishment and attenuation features of the pressure waveform to reconstruct the hysteresis response state of the physical environment, tubing compliance is incorporated into the network input space and mapped to generate a composite command containing a base flow rate and resistance torque. This eliminates drug delivery delays caused by tubing expansion and energy absorption, ensuring that motor actions are instantly converted into effective drug injection, thereby improving the real-time response speed and drug delivery control accuracy of anesthesia depth regulation.

This application discloses a wearable device and method integrating asthma attack monitoring and automated drug delivery. The method includes: acquiring a user's real-time multimodal biosignal vector stream; constructing a personalized steady-state feature signature for the user, the personalized steady-state feature signature being used to characterize the user's healthy physiological baseline; determining a steady-state perturbation scalar in real-time, characterizing the degree of deviation between the current physiological state and the healthy physiological baseline; generating a quantified asthma attack risk index based on the steady-state perturbation scalar through an asynchronous risk escalation engine; and when the asthma attack risk index meets preset intervention triggering conditions, determining that a coherence desynchronization event has occurred, and controlling a miniaturized injection actuator within the wearable device to perform automated drug delivery. This application, by constructing a physiological state phase-locked loop model, achieves adaptive monitoring and closed-loop automated intervention for asthma attacks, improving emergency response speed and monitoring specificity.

The application relates to the technical field of medical devices, in particular to a skin department traditional Chinese medicine external use dosing device with adjustable depth and a use method thereof, which comprises an outer pipe, a movable adjusting and limiting collecting assembly suitable for being embedded in an anal recess and capable of collecting waste liquid is arranged outside the outer pipe, a medicine injection pipe is arranged in the outer pipe, a medicine pushing driving assembly capable of positioning the position of the medicine injection pipe and pushing medicine is arranged on the outer pipe, an anti-backflow valve group is arranged on the medicine outlet end of the outer pipe and the medicine outlet end of the medicine injection pipe, and a driving dynamic sealing structure capable of dynamically sealing the medicine outlet end of the medicine injection pipe is further arranged in the outer pipe. Compared with the prior art, the skin department traditional Chinese medicine external use dosing device with adjustable depth and the use method thereof not only realize accurate depth positioning and anti-slip anchoring, but also form a negative pressure cavity through conical surface fitting, provide a sealed environment for a sewage discharge channel, forcibly guide the overflow sewage into a bypass for discharge, and completely solve the anal pollution problem.

This invention discloses an iontophoresis gel scleral contact lens and its preparation method, comprising a contact lens frame, a polymer porous microsphere drug-carrying layer loaded with nano-sustained-release drugs, an electrode layer, and a flexible material covering the electrode layer on the contact lens frame, and a gel layer covering the outer side of the contact lens frame. This iontophoresis gel scleral contact lens has a simple structure, facilitates convenient and rapid drug delivery, and provides sustained-release efficacy. It allows patients to self-administer the drug, directly delivering it to the intraocular lesion site, avoiding adverse reactions in other tissues or the whole body, and has a sustained-release function to reduce the frequency of drug administration.

The present invention relates to surface-functionalized extracellular vehicles. Specifically, the present invention relates to exosomes surface-functionalized with lactosylated polyetheneimine (PEI-LA), such surface-functionalized exosomes as drug delivery vehicles, 5 compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to liver.

A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member, the plunger including a body portion having an inner wall defining an axial chamber and an outer wall cooperating with the inner wall to define a body thickness. The device may further include a plunger biasing member disposed at least partially within the axial chamber, the plunger biasing member configured to urge the plunger toward the distal end of the drug storage container.

In one example, a drug delivery system, such as an on-body or off-body delivery system, is configured to deliver a therapeutic drug to a patient. This system comprises a curved track, a plunger, and a driver. The driver translates the plunger along the curved track, causing the plunger's flexible plunger rod to bend along the curved track, driving the plunger seal of the drug container to dispense the liquid drug from the container.

The present application relates to a kind of drug composition containing STING agonist and WIP1 inhibitor and its liposome and application.The composition can be co-encapsulated in liposome with STING agonist and WIP1 inhibitor, form stable drug delivery system.The liposome can promote efficient endocytosis of cell, and release two active ingredients in cytoplasm synchronously, block the negative feedback mechanism of STING signal path by WIP1 inhibitor, enhance and prolong the activation level of STING path, to synergistically inhibit tumor growth.Based on the mechanism, the drug composition of the present application can be used for preparing the drug for treating diseases related to STING path (such as tumor).

The application provides a preparation method of NK cell-derived nanovesicles and application thereof. Specifically, the application provides NK cell-derived nanovesicles (NK-NVs) which are similar to the characteristics and functions of NK cell-derived extracellular vesicles by an extrusion method / stress gradient membrane remodeling technology, and also provides a drug composition, a drug delivery system and corresponding use of the NK-NVs as a delivery carrier for delivering an antitumor drug. The preparation method of the application can mass-produce NK-NVs and kill various types of tumor cells. The NK-NVs have multiple advantages in drug delivery, so that they are expected to be a new choice for tumor immunotherapy, especially for tumor cells with drug resistance, and can significantly improve the sensitivity to chemotherapeutic drugs, and have a wide application prospect.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

The application relates to the technical field of drug delivery, and discloses a polymer microcrystal patch fused with a biodegradable material and a preparation method thereof, which comprises a microneedle array and a supporting substrate made of raw materials, and is characterized in that the microneedle array is made of raw materials containing a cationic polymer, an anionic polymer, an ion shielding agent and an active ingredient. The preparation method comprises the following steps: filling a solution containing a cationic polymer and an active ingredient into a microneedle negative mold; and covering the surface of the solution with a layer of a solution containing an anionic polymer and an ion shielding agent. By introducing the ion shielding agent, the application effectively controls the ion crosslinking rate between the polymers, solves the problem of incomplete microneedle forming caused by too fast reaction, and significantly improves the forming quality of the microneedles. The method is carried out at room temperature, the conditions are mild, the bioactivity of the active ingredient can be effectively protected, and the used materials are good in biocompatibility and high in safety.

A deployment system for accurate placement of localization tags within biological tissue is disclosed. The system comprises a catheter hub with sheath, a stylet, and a loader. The catheter hub provides an interface for system components, while the flexible sheath allows navigation to target sites. The stylet, operable in multiple positions, guides the sheath and assists in tag deployment. The loader houses the localization tag and acts as a safety spacer during deployment. The system is compatible with endoscopes and various imaging modalities, offering improved accuracy and efficiency over traditional wire localization techniques. The localization tags may be passive or active, with potential for advanced functionalities such as biosensing or drug delivery. This minimally invasive system finds applications in tumor marking, lymph node localization, and targeted therapy delivery across multiple medical specialties.

This invention discloses an amphoteric compound or its pharmaceutically acceptable salt, complex and its applications, wherein the amphoteric compound has a general structural formula as shown in formula (I); the amphoteric compound or its pharmaceutically acceptable salt of this invention can be used to prepare lipid nanoparticles for drug delivery, and the lipid nanoparticle delivery system has higher transfection efficiency, better delivery efficiency and better mRNA encapsulation rate compared with commercially available delivery systems.

A method, system, and apparatus for drug delivery and treatment may be provided. The drug delivery method may be used to treat health conditions such as periprosthetic joint infections (PJI) and other orthopedic joint infections. The drug delivery method and apparatus may include a fluid delivery mechanism, which may include a fluid reservoir which may be filled with a high-concentration antibiotic formulation. The high-concentration antibiotic formulation may include an antibiotic concentration ranging from about 10 mg / mL to about 200 mg / mL may be dissolved in an aqueous solution, and then may be stored in refrigerated or frozen conditions. The fluid from the reservoir may be delivered, using a medical device or instrument, in discrete doses for bolus administration.

The application belongs to the technical field of medicines, and discloses a mannose-modified nano silver cluster, a preparation method and application of the mannose-modified nano silver cluster as a probe, wherein the mannose-modified nano silver cluster is obtained by coupling bovine serum albumin-nano silver clusters and modified mannose through acid-amine condensation reaction, 14 modified mannose molecules are coupled on each bovine serum albumin molecule, the mannose-modified nano silver cluster can be applied as a probe in biological recognition and target labeling, a new visual tool is provided for receptor-ligand interaction research and drug delivery monitoring, and the application development of the sugar probe in biomedical detection and diagnosis and treatment is promoted.

Plunger drive systems used with injectors to expel a fluid drug for injection into a patient include a housing and a plunger rod that extends from the housing. The plunger rod includes a first leg and a second leg individually coupled with separate rollers over one portion of the first leg and second leg and engaged together over another portion of the first leg and second leg to form a column. The legs may include a reinforcement member. The first leg and second leg meet at a location between the rollers and are engaged with one another through complementary registration surfaces. When the rollers are rotated, typically through action of an electric motor, the rollers rotate in opposite directions to increase a length of the column. The column may be operatively coupled to a plunger of a syringe to dispense a fluid drug as the column increases in length.

The application relates to a corneal drug delivery scleral lens, which comprises a lens body, the lens body comprises a treatment area, a reverse area and a landing area from the center to the outside, the treatment area is located in the center, the reverse area is arranged around the treatment area and is used for connecting the treatment area and the landing area, the landing area is arranged around the reverse area and is used for supporting a scleral surface, so that a liquid accumulation layer is formed between a corneal front surface and the lens body; a flow guide pipe is arranged in the lens body in the radial direction, forming a liquid injection end and a drug delivery hole. The scleral lens of the application can supplement liquid medicine through the flow guide pipe without taking off the lens, dynamic fluid replacement is realized, and the cornea is prevented from being damaged by repeated taking off and wearing. When the lens is designed, the height of the reverse area is taken as a core variable parameterization design, the thickness of the liquid accumulation area and the drug concentration are accurately controlled. The overflow hole is normally sealed, and the risk of infection is reduced. The liquid medicine is diffused from the edge to the center, the whole surface of the cornea is uniformly soaked, and the bioavailability is improved.

This invention relates to the field of traditional Chinese medicine (TCM) plaster technology, specifically to a method for preparing a highly permeable TCM plaster. The method includes the following steps: S1. Technology summary and model construction; S2. Disease analysis and technology selection; S3. Material selection and semi-finished product preparation; S4. Material mixing and addition; S5. Plaster classification and preparation; and S6. TCM patch preparation, verification, and preservation. This invention constructs a bidirectional gradient structure with particle size ranging from coarse to fine and drug concentration from low to high. This allows the drug to form a stable concentration difference from the drug storage layer to the skin surface during application, avoiding the problems of initial drug burst release and insufficient later release caused by the single particle size of traditional pastes. It also prevents the contact layer from rapidly losing water and forming a dense, hard shell due to excessive high-concentration drugs or fine powder, thereby significantly improving the cumulative transdermal rate within 24 hours and achieving long-acting, highly permeable transdermal drug delivery.

The preparation and application of spaced double disulfide bond bridged dimer prodrug and self-assembled nanoparticles thereof belong to the technical field of medicine, and relate to the synthesis of the connection of the spaced double disulfide bond bridged dimer prodrug shown in structural general formula (I) and the construction of the spaced double disulfide bond bridged dimer prodrug shown in structural general formula (II) and self-assembled nanoparticles thereof, and the application thereof in drug delivery. The preparation method is simple and easy to implement, the spaced double disulfide bond bridged dimer prodrug can be self-assembled to form nanoparticles, and has the ability of redox dual response drug release, so that the intelligent response activation of the prodrug in tumor cells can be realized, and the anti-tumor effect and safety of the prodrug are ensured. The anti-tumor effect, pharmacokinetic parameters and safety thereof are superior to those of the prodrug nanoparticles bridged by a single disulfide bond. The present application provides a new strategy for developing a high-efficiency low-toxicity drug delivery system, and meets the urgent needs of high-end chemotherapy preparations in clinical practice.

This application provides a method for preparing pH-responsive polyamino acid drug-loaded nanoparticles based on sarcosine and their application. Sar-NNCA, L-lysine-NCA, and L-phenylalanine-NCA are dissolved in anhydrous DMF and polymerized under argon protection with a hexamethyldisilazine initiator to obtain a polyamino acid block copolymer Sar-NNCA. 80 -Lys(Cbz) n -Phe 10 The crude product was deprotected under HBr / acetic acid and loaded with DOX to obtain Sar. 80 -Lys n -Phe 10 -DOX. This application describes the preparation of a pH-responsive polymer nanoplatform, Sar, by encapsulating doxorubicin in polysarcosine-polylysine-polyphenylalanine nanoparticles via Schiff base bonds. 80 -Lys n -Phe 10 -DOX is used for tumor treatment. These polyamino acid nanoparticles are spherical with an average particle size of approximately 200 nanometers, exhibiting pH-responsive properties, excellent cellular uptake capacity, and anti-tumor effects. In vitro experiments show that Sar... 80 -Lys n -Phe 10 The carrier material exhibits excellent biocompatibility. The newly synthesized Sar... 80 -Lys n -Phe 10 -DOX nanomicelles show promise as a drug delivery system for cancer treatment.

This application relates to an inhalation device and a drug delivery system. The inhalation device includes a mixer, an ultrasonic nebulizer, and a heated nebulizer. The mixer has a mixing chamber; the ultrasonic nebulizer has a first nebulization chamber and a first nebulization channel communicating with the first nebulization chamber, the first nebulization channel communicating with the mixing chamber, and the first nebulization chamber is used to hold a first liquid; the heated nebulizer has a second nebulization chamber and a second nebulization channel communicating with the second nebulization chamber, the second nebulization channel communicating with the mixing chamber, the second nebulization chamber is used to hold a second liquid, the second liquid being a solvent for the first liquid. The above-mentioned inhalation device can improve drug droplet solubility, control particle size distribution, adjust the drug nebulization and solvent mixing ratio in real time, and reduce the likelihood of large droplet drug residues in the throat.

The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

The present invention relates to a medicament delivery device comprising a housing (60), which housing is arranged to accommodate a medicament container (62); a drive unit (86) operably arranged to act on said medicament container (62) for expelling a dose of medicament; an activation unit (74) operably connected to said drive unit for activating said drive unit (86); said drive unit (86) comprising an actuation element (84) arranged movable inside the housing (60) from an initial position prior to activation, to a displaced position after activation; at least a first NFC-chip (170, 172) comprising specific information arranged on said actuation element; at least one shielding element (174) arranged to said housing, such as to shield said at least first NFC-chip (170, 172) from being read by an NFC-chip reader when said actuation element (84) is either in the initial position or in the displaced position. The present invention also comprises a communication system in which said medicament delivery device is a part.